The Green Journal
The Green Journal
Audio Summaries
Obstetrics and gynecology
Every issue of The Green Journal moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from The Green Journal.
The Obstetrician-Gynecologist's Role in Adoption.
Nov 19, 2026
This ACOG Committee Statement addresses how obstetrician-gynecologists should handle adoption-related discussions when pregnant patients are considering relinquishing parental rights and placing their child for adoption. The authors examine the ethical issues involved and ask how physicians can provide professional recommendations and safeguards while keeping the patient at the center through a trauma-informed approach.
Hypertensive Disorders of Pregnancy and Black-White Racial Disparities in Severe Maternal Morbidity.
Nov 17, 2026
This study asks how much of the Black-White racial disparity in severe maternal morbidity (SMM) in Massachusetts could be eliminated if hypertensive disorders of pregnancy (HDP) were prevented. Using causal mediation analysis of 1.24 million deliveries (1998-2021), the authors found that preventing HDP would eliminate about 40% of the absolute disparity in SMM (excluding transfusion-only events), with larger shares for cardiac complications (about 58%). Preventing only severe HDP accounted for a smaller but still meaningful share (about 28%), suggesting that HDP prevention could substantially reduce racial disparities in SMM.
The Rising Tide of Cardiovascular Risk in Younger Women.
Nov 17, 2026
This commentary examines whether rising cardiovascular disease risk in younger and premenopausal women should change how menopausal hormone therapy (HT) is considered, especially after recent FDA labeling changes that removed boxed warnings. The author argues that women are reaching menopause with more advanced cardiovascular risk, driven by adverse pregnancy outcomes, metabolic changes, and increasing obesity. She recommends identifying and treating modifiable risk factors and using validated risk calculators to guide lipid-lowering therapy and the choice and advisability of HT.
Inflammatory Bowel Disease in Pregnancy.
Nov 17, 2026
This review addresses how inflammatory bowel disease should be managed across pregnancy, covering fertility, medication safety, and delivery planning. The authors conclude that active disease is the strongest predictor of poor pregnancy outcomes, so maintaining remission is the central goal. They recommend continuing most established therapies (aminosalicylates, thiopurines, and biologics), avoiding methotrexate, Janus kinase inhibitors, and sphingosine-1-phosphate receptor modulators, and individualizing delivery planning with coordinated multidisciplinary care.
A Randomized Trial of Fractionated CO2 Laser With Topical Clobetasol Compared With Fractionated CO2 Laser With Placebo for Treatment of Vulvar Lichen Sclerosus.
Nov 17, 2026
This double-blind, randomized trial asked whether adding topical clobetasol propionate 0.05% to fractionated CO2 laser treatment improves skin-related outcomes in women with vulvar lichen sclerosus compared with laser plus placebo ointment. The primary outcome, a 16-point or greater improvement on the Skindex-29, did not differ between groups (30.3% clobetasol vs 27.5% placebo, P=.67), though the clobetasol group reported greater improvement in symptom scores, higher treatment satisfaction, and low, similar adverse event rates. Overall, the findings suggest clobetasol may add symptom relief and satisfaction to laser therapy, but it did not meet the primary efficacy endpoint.
Hospital-Level Variation in Antenatal Corticosteroid Use for Late Preterm Births.
Nov 10, 2026
This retrospective cohort study of 726 U.S. hospitals (2015–2022, Premier Healthcare Database) asked whether and how much hospitals differ in giving antenatal betamethasone to late preterm (34–36 weeks) singleton births after the ALPS trial. Hospital adoption rates ranged from 0% to 92%, with median rates rising from 15.4% in the lowest quartile to 54.3% in the highest, showing substantial heterogeneity. Urban location and a higher share of births at 34 weeks were associated with high adoption, while Southern hospitals had lower odds, suggesting that local factors beyond observable hospital characteristics likely drive uptake of this evidence-based practice.
Improving Mental Health Support for Neonatal Intensive Care Unit Mothers Through a Universal Screening Quality-Improvement Initiative.
Nov 10, 2026
This quality-improvement study asked whether integrating a dedicated mental health clinician into a level 3 NICU could improve universal perinatal mood and anxiety disorder screening and referral for mothers. After implementation, screening rose from 29.5% to 95.0% of mothers, and the proportion referred for psychosocial support rose from 25.3% to 59.9%. The authors conclude that a dedicated clinician, backed by multidisciplinary buy-in, may enable sustainable universal screening, though screen-positive mothers were more likely to be Black non-Hispanic and screen-negative mothers more likely to be White non-Hispanic.
Association Between Adverse Pregnancy Outcomes and Postpartum Contraceptive Method Selection and Use.
Nov 10, 2026
This study used 2016-2022 PRAMS data (222,412 individuals) to examine whether adverse pregnancy outcomes, such as hypertension, diabetes, preterm birth, prolonged infant hospitalization, and infant death, are associated with postpartum contraceptive use and method choice. The authors found that experiencing three or more adverse outcomes was linked to lower odds of contraceptive use, with infant death showing the strongest association (aOR 0.39), while users with at least one adverse outcome were more likely to choose permanent contraception over patient-start methods. The findings suggest that patient-centered counseling and shared decision-making are needed to support postpartum reproductive goals after adverse pregnancy outcomes.
Patient Report of Subsequent Uterine-Sparing Leiomyomata Procedures up to 10 Years.
Nov 10, 2026
This study followed 817 women from two uterine leiomyomata procedure studies for 4 to 10.5 years to determine how often uterine-sparing treatments (myomectomy, endometrial ablation, RFA, or UAE) were followed by additional treatment, including hysterectomy. Overall, 28.7% needed retreatment, most often hysterectomy, and RFA carried a higher retreatment risk than myomectomy (HR 1.61). The majority of women (64.1% at 10 years) remained free of further uterine procedures, suggesting uterine-sparing options offer durable relief for many patients.
Hepatitis C Treatment Access With Implementation of an Antenatal Linkage-to-Care Bundle.
Nov 3, 2026
This quality-improvement study asked whether a health system-wide antenatal bundle (HALT-C) could increase direct-acting antiviral prescribing for pregnant patients with hepatitis C by 6 months postpartum. Comparing pre-implementation (62 pregnancies) and post-implementation (35 pregnancies) periods, prescribing rose from 48.4% to 77.1% (P=.009), and treatment completion improved from 21.0% to 54.3%. Patients treated during pregnancy were twice as likely to complete therapy as those who deferred treatment until after delivery (92.3% vs 45.5%), and no perinatal transmissions occurred among infants whose mothers were treated antenatally.
